MKEA.PA
Price:
$0.622
Market Cap:
$9.13M
Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.
Industry
Medical - Devices
IPO Date
2011-07-06
Stock Exchange
PAR
Ticker
MKEA.PA
According to Mauna Kea Technologies S.A.’s latest financial reports and current stock price. The company's current ROE is 38.61%. This represents a change of 268.40% compared to the average of 10.48% of the last 4 quarters.
The mean historical ROE of Mauna Kea Technologies S.A. over the last ten years is -946.66%. The current 38.61% ROE has changed -104.08% with respect to the historical average. Over the past ten years (40 quarters), MKEA.PA's ROE was at its highest in in the September 2023 quarter at 18.89%. The ROE was at its lowest in in the June 2023 quarter at -8.55%.
Average
-946.66%
Median
49.39%
Minimum
-6036.36%
Maximum
130.13%
Discovering the peaks and valleys of Mauna Kea Technologies S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 97.75%
Maximum Annual ROE = 130.13%
Minimum Annual Increase = -101.75%
Minimum Annual ROE = -6036.36%
Year | ROE | Change |
---|---|---|
2024 | 42.66% | 97.75% |
2023 | 21.57% | -61.56% |
2022 | 56.11% | -56.88% |
2021 | 130.13% | 22.87% |
2020 | 105.91% | -101.75% |
The current ROE of Mauna Kea Technologies S.A. (MKEA.PA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
40.11%
5-year avg
71.28%
10-year avg
-946.66%
Mauna Kea Technologies S.A.’s ROE is less than Nanobiotix S.A. (76.53%), greater than ERYTECH Pharma S.A. (-73.03%), less than AB Science S.A. (32.39%), greater than Innate Pharma S.A. (-262.93%), less than Adocia S.A. (127.55%),
Company | ROE | Market cap |
---|---|---|
76.53% | $220.72M | |
-73.03% | $48.66M | |
32.39% | $82.74M | |
-262.93% | $141.19M | |
127.55% | $71.53M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mauna Kea Technologies S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mauna Kea Technologies S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Mauna Kea Technologies S.A.'s ROE?
How is the ROE calculated for Mauna Kea Technologies S.A. (MKEA.PA)?
What is the highest ROE for Mauna Kea Technologies S.A. (MKEA.PA)?
What is the 3-year average ROE for Mauna Kea Technologies S.A. (MKEA.PA)?
What is the 5-year average ROE for Mauna Kea Technologies S.A. (MKEA.PA)?
How does the current ROE for Mauna Kea Technologies S.A. (MKEA.PA) compare to its historical average?